SLS International (AMEX:SLS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.02), Fidelity Earnings reports.
SLS International Company Profile
SELLAS Life Sciences Group, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer.
Featured Article: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with MarketBeat.com's FREE daily email newsletter.